https://doi.org/10.55788/a84d4048
Considering bypass grafting to the left anterior descending artery, the use of the internal thoracic artery is the long-accepted primary choice. “But controversy exists on the choice for the second conduit,” stated. The RAPCO trial (NCT00475488) consisted of 2 separate integrated trials that compared the use of the radial artery versus the free right internal thoracic artery (RAPCO-RITA) and, separately, the radial artery versus a saphenous vein graft (RAPCO-SVG). Prof. Hare presented the 15-year clinical outcomes.
RAPCO-RITA randomised 394 participants, under 70 years of age (under 60 years of age for those with diabetes) 1:1 to radial artery or free RITA grafting. The baseline data showed a mean age of participants of 59 years, around 10% were women, and 11% of participants had diabetes. The composite clinical outcome of major adverse cardiac events (MACE) consisted of all-cause mortality, acute myocardial infarction, and/or repeat coronary revascularisation.
The rate of MACE was significantly reduced by the use of radial artery versus RITA with a hazard ratio of 0.74 (95% CI 0.55-0.97; P=0.04). “Looking at the composition of the MACE, all-cause mortality, which had an absolute reduction of 8% after 15 years and a relative risk reduction of 31%, probably predominates in the MACE calculation,” Prof. Hare elaborated.
In RAPCO-SVG, 225 participants were included, and, in line with the somewhat different inclusion criteria, the mean age was around 73 years, 19% were women, and 45% of participants had diabetes. After allocation to grafting with either a radial artery or SV, the rate of MACE was again significantly lower with radial artery grafting versus SVG: HR 0.71 (95% CI 0.52-0.98; P=0.04) at 15 years.
Prof. Hare mentioned that, currently, less than 10% of the 200,000 annual coronary artery bypass surgeries performed in the US involve radial artery grafts. From the RAPCO trial results, he suggested that all isolated CAGB operations should consider using a radial graft and assess if it is suitable and can be used without contraindications. “Whether radial grafts also perform better than current methods in instrumented procedures, however, needs to be further researched,” closed Prof. Hare.
- Hare DL, et al. Radial artery patency and clinical outcomes (RAPCO) randomised trials - The 15-year clinical outcomes comparing radial artery with right internal thoracic artery or with saphenous vein grafting. LBS.03, AHA Scientific Sessions 2022, 05–07 November, Chicago, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Methylprednisolone does not reduce risk of adverse outcomes in infants undergoing heart surgery Next Article
Mindfulness programme contributes to office blood pressure lowering »
« Methylprednisolone does not reduce risk of adverse outcomes in infants undergoing heart surgery Next Article
Mindfulness programme contributes to office blood pressure lowering »
Table of Contents: AHA 2022
Featured articles
What Is New in Heart Failure
Torsemide not superior to furosemide after hospitalisation for heart failure
IRONMAN failed primary endpoint but shows potential long-term benefits of iron repletion in HF patients
Up-titration of HF therapies following HF discharge saves lives
Hypertension: Novel Developments
The endothelin system: a new target for resistant high blood pressure
Can renal denervation lower BP on top of antihypertensive drugs?
Quadruple, ultra-low-dose treatment did not meet primary endpoint in hypertension
Mindfulness programme contributes to office blood pressure lowering
Interventional Cardiology in 2022
Grafting with the radial vein: an underrated option in CABG surgery?
Extracorporeal membrane oxygenation not superior to conservative therapy in cardiogenic shock
Surgery with adequate saphenous vein partly better than endovascular treatment in CLTI
Arrhythmia – State of the Art
First-line ablation limits progression to persistent AF
Doubling the dose of self-administered etripamil terminates PSVT
Novel Developments in Primary and Secondary Prevention
Grafting with the radial vein: an underrated option in CABG surgery?
Digitally delivered cognitive behavioural therapy successful in type 2 diabetes
Empagliflozin reduces risk of kidney disease progression and CV events in patients with CKD
RESPECT-EPA misses primary endpoint but hints towards improvements in CV outcomes by EPA
Pemafibrate fails to reduce cardiovascular events in diabetes but may benefit the liver
Dietary supplements not effective in lowering LDL-C, use of low-dose statins encouraged
No sex differences in lipid-lowering effect and treatment benefit of PCSK9 inhibitors
COVID-19 and the Heart
‘No’ to routine use of rivaroxaban in outpatients with COVID-19
COVID-19 pandemic: Older adults and those affected by the delta variant experienced increased cardiovascular morbidity and mortality
COVID-19 mRNA vaccination does not amplify risk of cardiovascular hospitalisation
Best of the Posters
Higher LDL-cholesterol levels linked to higher CVD mortality risk in the elderly
AF: Moderate alcohol intake possibly associated with a reduced mortality risk
Periodontitis: An independent risk factor for AF
Related Articles
January 11, 2023
Up-titration of HF therapies following HF discharge saves lives
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com